RHOT1_R272Q_clone1_PD
LCSBi009-A
General
Cell Line |
|
| hPSCreg name | LCSBi009-A |
| Cite as: | LCSBi009-A (RRID:CVCL_C8G3) |
| Alternative name(s) |
RHOT1_R272Q_clone1_PD
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
STBCi004-B-1 (SFC832-03-06 LRRK2WT/WT C47) Donor's gene variants: LRRK2 Donor diseases: Parkinson disease EDi001-A-2 (AST23-1KO-3, AST22-1KO-3, AST-23_SCAKO Clone 3, AST-22_SNCAKO Clone 3) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-3 (AST23_SNCAKO Clone 1, AST22-1KO-1, AST23-1KO-1, AST22_SNCAKO Clone 1) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease EDi001-A-4 (AST22-2KO-6, AST23_SNCAKO Clone 6, AST22_SNCAKO Clone 6, AST23-2KO-6) Donor's gene variants: SNCA, SNCA, SNCA, SNCA Donor diseases: Parkinson disease |
| Last update | 8th April 2023 |
| User feedback | |
Provider |
|
| Generator | Luxembourg Centre for Systems Biomedicine (LCSB) |
| Owner | Luxembourg Centre for Systems Biomedicine (LCSB) |
| Distributors | |
| Derivation country | Luxembourg |
External Databases |
|
| BioSamples | SAMEA112885173 |
| Cellosaurus | CVCL_C8G3 |
| Wikidata | Q123032932 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes Cell line can only be used in: Align with cell line owner for Material Transfert agreement
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
|
| Subclones | |
Donor Information
General Donor Information |
|
| Sex | female |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
Karyotyping (Donor) |
|
| Has the donor karyotype been analysed? |
Yes
|
External Databases (Donor) |
|
| BioSamples | SAMEA112885174 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | rejko.krueger@uni.lu / rejko.krueger@lih.lu |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | CNER Comité National d'Ethique et de Recherche |
| Approval number | 201411/05 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type | |
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | in vitro transcribed RNA replicon expressing the reprogramming factors in a single self-replicating polycistronic transcript |
| Is reprogramming vector detectable? |
No |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
Essential 8™
|
| Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | Yes |
| Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
Differentiation Potency
In vitro directed differentiation
| Marker | Expressed |
| Brachiury |
Yes |
Morphology
iPSCs were plated on Matrigel-coated coverslips two days before the in vitro differentiation procedure started. The Human Pluripotent Stem Cell Functional Identification Kit (R&D Systems, Cat No. SC027B) was used to verify iPSCs capacity to differentiate into the three germ layers. ICC of the ectodermal marker OTX2, the mesodermal marker Brachyury and the endodermal marker SOX17 was performed. Nuclei were stained with Hoechst and images were acquired using a Zeiss AxioObserverZ1 microscope.
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
female
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.